Device Trial Radar · NCT04649255
Treatment of Peripheral Arterial Hemorrhage With Lava LES (The LAVA Study)
Last checked: Nov 20, 2026Latest source record: Apr 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
113
Actual
Start
Apr 14, 2021
Primary completion
Aug 17, 2022
Study completion Aug 17, 2022
Sponsor
- Lead sponsor
- BlackSwan Vascular, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Syntactx
- First posted
- Dec 2, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and effectiveness of the Lava LES for the embolic treatment of arterial hemorrhage in the peripheral vasculature.
Conditions
- Peripheral Arterial Hemorrhage
Interventions
Liquid EmbolicDevice
Lava Liquid Embolic System (LES)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Composite of Freedom From Major Adverse Events (MAEs)Time frame: 30 Days
1 more outcomes with a free account
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of California
Irvine, California
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.